Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Adagene Inc ADR (ADAG)
Adagene Inc ADR (ADAG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 62,717
  • Shares Outstanding, K 43,253
  • Annual Sales, $ 10,180 K
  • Annual Income, $ -73,180 K
  • 60-Month Beta 0.07
  • Price/Sales 7.03
  • Price/Cash Flow N/A
  • Price/Book 0.79
Trade ADAG with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/23
See More
  • Average Estimate -0.46
  • Number of Estimates 1
  • High Estimate -0.46
  • Low Estimate -0.46
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2400 +12.99%
on 03/13/23
1.8700 -25.07%
on 03/03/23
-0.2626 (-15.78%)
since 02/28/23
3-Month
1.1500 +21.83%
on 12/29/22
2.1000 -33.28%
on 01/27/23
+0.2511 (+21.83%)
since 12/28/22
52-Week
0.9000 +55.68%
on 10/31/22
4.4330 -68.39%
on 03/29/22
-2.5889 (-64.88%)
since 03/28/22

Most Recent Stories

More News
Are Medical Stocks Lagging Adagene (ADAG) This Year?

Here is how Adagene Inc. Sponsored ADR (ADAG) and Alcon (ALC) have performed compared to their sector so far this year.

ADAG : 1.4011 (-3.37%)
ALC : 70.97 (+0.24%)
Adagene Announces Authorization of Share Repurchase Program up to US$10 Million

SAN DIEGO and SUZHOU, China, June 29, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and...

ADAG : 1.4011 (-3.37%)
Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody® ADG126, with Repeat Dosing Across Dose Levels

       - First clinical data demonstrating potential of SAFEbody technology platform to create best-in-class therapeutics -        - Additional data from...

ADAG : 1.4011 (-3.37%)
Adagene to Participate in Investor Conferences in May and June

SAN DIEGO and SUZHOU, China, May 12, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and...

ADAG : 1.4011 (-3.37%)
Adagene Presents Data Demonstrating First and Best-in-Class Potential for Differentiated Preclinical Antibody Candidates at American Association for Cancer Research (AACR) Annual Meeting 2022

- Poster presentations showcase SAFEbody® precision masking technology applicability across targets and modalities – - IND or equivalent filings...

ADAG : 1.4011 (-3.37%)
Adagene Reports Full Year 2021 Financial Results and Provides Corporate Update

- 2022 clinical data readouts on track to show potential best-in-class safety profile for anti-CTLA-4 programs (ADG116, ADG126) with PD-1 for proven and...

ADAG : 1.4011 (-3.37%)
Adagene (ADAG) Gets FDA Nod for Cancer Study on ADG126 Combo

The FDA grants clearance to Adagene (ADAG) to begin clinical studies on its anti-CTLA-4 mAb, ADG126 in combination with pembrolizumab to treat advanced/metastatic solid tumors.

MRK : 105.78 (-0.13%)
VRTX : 312.46 (+0.10%)
KLDO : 0.0002 (unch)
ADAG : 1.4011 (-3.37%)
Adagene Announces Four Poster Presentations on Robust Preclinical Pipeline of Antibody-Based Therapeutics at Upcoming American Association for Cancer Research (AACR) Annual Meeting

- New IND-enabling programs reinforce commitment to build a deep, broad and differentiated pipeline that transforms cancer immunotherapy leveraging...

ADAG : 1.4011 (-3.37%)
Adagene Becomes Oversold (ADAG)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical...

ADAG : 1.4011 (-3.37%)
Adagene Announces SAFEbody® Multi-Target Collaboration with Sanofi for Novel Masked Immuno-Oncology Antibody Candidates

- Total potential transaction value of $2.5 billion plus royalties -    SAN DIEGO and SUZHOU, China, March 02, 2022 (GLOBE NEWSWIRE) -- Adagene Inc....

ADAG : 1.4011 (-3.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Adagene Inc. is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene Inc. is based in SAN FRANCISCO, Calif.

See More

Key Turning Points

3rd Resistance Point 1.7867
2nd Resistance Point 1.6833
1st Resistance Point 1.5667
Last Price 1.4011
1st Support Level 1.3467
2nd Support Level 1.2433
3rd Support Level 1.1267

See More

52-Week High 4.4330
Fibonacci 61.8% 3.0834
Fibonacci 50% 2.6665
Fibonacci 38.2% 2.2496
Last Price 1.4011
52-Week Low 0.9000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar